Advances in anaemia management: Current evidence

Nephrology

Volumn 7, Issue 5, 2002, Pages 257-261

  McMahon, Lawrence P ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Administration; Anaemia; Aranesp; Efficacy; Epoetin; Iron status

Indexed keywords

ASCORBIC ACID; FERRITIN; FERROUS GLUCONATE; HEMOGLOBIN; IRON DEXTRAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSFERRIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 0036048199     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1797.2002.00092.x     Document Type: Review

References (70)

1. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients
2. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients
3. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration
4. Hematocrit stability following intravenous versus subcutaneous administration of epoetin alfa to dialysis patients: A post hoc analysis
5. Crossover comparison of intravenous and subcutaneous recombinant human erythropoietin in a small haemodialysis unit
6. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 ESRD core indicators project
7. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis
8. Subcutaneous treatment with recombinant human erythropoietin. The influence of injection frequency and skin-fold thickness
9. Body mass is a significant factor in the response to IV SC EPO
10. Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients
11. Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly
12. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: Results from a randomized controlled multicentre trial
13. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis
14. Optimizing erythropoietin therapy
15. Daily subcutaneous administration of recombinant human erythropoietin (rhEPO) in peritoneal dialysis patients: A Europoean dose-response study
16. The pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in paediatric patients with chronic renal failure (CRF) or end-stage renal disease
17. Comparison of the phar-macokinetics of novel erythropoiesis stimulating protein (NESP) and epoetin alfa in dialysis patients
18. Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anaemia
19. Novel erythropoiesis stimulating protein (NESP) administered subcutaneously corrects anemia in subjects with chronic renal insufficiency (CRI) when administered at a reduced dose frequency compared with recombinant-human erythropoietin (r-HuEPO)
20. Novel erythropoiesis stimulating protein (NESP) corrects anemia in dialysis patients when administered at reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO)
21. Management of iron substitution during rHuEPO therapy in chronic renal failure patients
22. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation
23. A randomised controlled study of iron supplementation in patients treated with erythropoietin
24. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialyis
25. Intravenous ferric saccharate as an iron supplement in dialysis patients
26. Regular, low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients
27. Importance of iron supply for erythropoietin therapy
28. Economic appraisal of maintenance parenteral iron administration in treatment of the anaemia in chronic haemodialysis patients
29. Hematologic and erythropoietin responses to iron dextran in the hemodialysis environment
30. Iron deficiency in maintenance hemodialysis patients: Assessment of diagnostic criteria and of three different iron treatments
31. Intravenous iron for CAPD populations: Proactive or reactive strategies?
32. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients
33. K/DOQI clinical practice guidelines for anemia of chronic kidney disease 2000
34. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit
35. A study of parenteral iron regimens in hemodialysis patients
36. Iron and infection
37. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency
38. Iron administration and hospitalization in haemodialysis patients
39. Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients
40. Intervention thresholds and ceilings can determine the haemoglobin outcome distribution in a haemodialysis population
41. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer®) vs iron gluconate (Ferrlecit®) in haemodialysis patients treated with rHuEPO
42. Safety of intravenous injection of iron saccharate in hemodialysis patients
43. Serious adverse reactions after intravenous ferric gluconate
44. A parallel comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload
45. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia
46. The effect of vitamin C intake on plasma oxalate in patients on regular haemodialysis
47. Evidence that serum calcium oxalate supersaturation is a consequence of oxalate retention in patients with chronic renal failure
48. Vitamin B6 and hemodialysis: The impact of high-flux/high-efficiency dialysis and review of the literature
49. Is there a role for adjuvant therapy in patients being treated with epoetin?
50. Metabolism of vitamin B6 and its requirement in chronic renal failure
51. Folic acid supplementation improves erythropoietin response
52. Is folate supplementation necessary in hemodialysis patients on erythropoietin therapy
53. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease
54. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients
55. Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: A prospective study
56. Ca++ and 1,25 (OH) 2D3 regulate in vitro and in vivo the response to human recombinant erythropoietin in CAPD patients
57. The effect of calcitriol on renal anaemia in patients undergoing long-term dialysis
58. High-dose alfacalcidol improves anaemia in patients on haemodialysis
59. Intravenous calcitriol improves anemia and reduces the need for erythropoietin in hemodialysis patients
60. Anemia and carnitine supplementation in hemodialyzed patients
61. Effects of L-carnitine on sodium transport in erythrocytes from dialyzed uremic patients
62. Erythropoietin and oxidative stress in haemodialysis: Beneficial effects of vitamin E supplementation
63. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis
64. Zinc status relates to hematological deficits in middle-aged women
65. Zinc-induced sideroblastic anemia: Report of a case, review of the literature, and description of the hematologic syndrome
66. Subtherapeutic erythropoietin and insulin-like growth factor-1 correct the anemia of chronic renal failure in the mouse
67. Analysis of circulating hematopoietic progenitors in patients with chronic renal failure under hemodialysis
68. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients?
69. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients
70. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: Any evidence of erythropoietin resistance?